These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians. Bested AC, Marshall LM. Rev Environ Health; 2015 Dec; 30(4):223-49. PubMed ID: 26613325 [Abstract] [Full Text] [Related]
3. Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Maes M, Twisk FN, Ringel K. Psychother Psychosom; 2012 Dec; 81(5):286-95. PubMed ID: 22832503 [Abstract] [Full Text] [Related]
4. Comorbidities treated in primary care in children with chronic fatigue syndrome / myalgic encephalomyelitis: A nationwide registry linkage study from Norway. Bakken IJ, Tveito K, Aaberg KM, Ghaderi S, Gunnes N, Trogstad L, Magnus P, Stoltenberg C, Håberg SE. BMC Fam Pract; 2016 Sep 02; 17(1):128. PubMed ID: 27590471 [Abstract] [Full Text] [Related]
5. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Organic Disease or Psychosomatic Illness? A Re-Examination of the Royal Free Epidemic of 1955. Underhill R, Baillod R. Medicina (Kaunas); 2020 Dec 26; 57(1):. PubMed ID: 33375343 [Abstract] [Full Text] [Related]
6. In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. Maes M, Ringel K, Kubera M, Anderson G, Morris G, Galecki P, Geffard M. J Affect Disord; 2013 Sep 05; 150(2):223-30. PubMed ID: 23664637 [Abstract] [Full Text] [Related]
7. A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors. Wirth K, Scheibenbogen C. Autoimmun Rev; 2020 Jun 05; 19(6):102527. PubMed ID: 32247028 [Abstract] [Full Text] [Related]
9. Possible role for early-life immune insult including developmental immunotoxicity in chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME). Dietert RR, Dietert JM. Toxicology; 2008 May 02; 247(1):61-72. PubMed ID: 18336982 [Abstract] [Full Text] [Related]
10. Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series. Gil A, Hoag GE, Salerno JP, Hornig M, Klimas N, Selin LK. Brain Behav Immun Health; 2024 Mar 02; 36():100720. PubMed ID: 38327880 [Abstract] [Full Text] [Related]
11. Inflammatory and oxidative and nitrosative stress cascades as new drug targets in myalgic encephalomyelitis and chronic fatigue syndrome. Maes M. Mod Trends Pharmacopsychiatry; 2013 Mar 02; 28():162-74. PubMed ID: 25224898 [Abstract] [Full Text] [Related]
16. Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Cliff JM, King EC, Lee JS, Sepúlveda N, Wolf AS, Kingdon C, Bowman E, Dockrell HM, Nacul L, Lacerda E, Riley EM. Front Immunol; 2019 Mar 02; 10():796. PubMed ID: 31057538 [Abstract] [Full Text] [Related]